☆ 4.7 Letter

Clinically indicated ibrutinib dose interruptions and reductions do not compromise long-term outcomes in CLL

BLOOD (2019)

Get Full Text
Add to Collection

Journal

BLOOD
Volume 133, Issue 22, Pages 2452-2455

Publisher

AMER SOC HEMATOLOGY
DOI: 10.1182/blood.2019896688

Keywords

-

Categories

Hematology

Funding

  1. National, Heart, Lung and Blood Institute, National Institutes of Health
  2. Pharmacyclics
  3. NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [ZIAHL002346] Funding Source: NIH RePORTER

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available
Webinars Posters Questions Hubs Funding Journals Papers Connect Collections Reviewers About Us FAQs Mobile App Privacy Policy Terms of Use
© Peeref 2019-2024. All rights reserved.